@SassyCell @SassyCell

fiercebiotech.com/biotech/agenus…

BOT/BAL for mCRC: not good news. Agenus will "prioritize" neoadjuvant BOT+BAL (in previously untreated high-risk S II and III MSS CRC) with new phase III trial, ROBBIN,  and plans to discontinue financial support for the ongoing BATTMAN Ph 3 study in late-line metastatic MSS CRC.

OK, $AGEN is "discontinuing financial support" for a study that's actively enrolling 834 patients. I'm sure that's ethically fine. Good luck to all involved!

A Phase 1, Open-label, Dose-Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, & Preliminary Efficacy of D3S-003 Monotherapy in Participants W/ Advanced Solid Tumors W/ a KRAS p.G12D Mutation 42 patients US, South Korea, Australia Opened May, 2026 clinicaltrials.gov/study/NCT07456…

#ASCO26 BREAKWATER: Encorafenib + cetuximab + FOLFIRI in 1L BRAF V600E-mutant mCRC Abstract LBA3503 Presentation: May 31, 2026 BRAF V600E-mutant CRC has always been different. More aggressive biology. Worse prognosis. Less forgiving clinical course. For years, the question was whether we could move targeted therapy earlier and make a real dent in outcomes, not just response. BREAKWATER keeps answering that question. This cohort evaluated encorafenib + cetuximab with FOLFIRI in the first-line setting for BRAF V600E-mutant mCRC. Quick hits: 📌 1L BRAF V600E-mutant mCRC Encorafenib + cetuximab + FOLFIRI vs FOLFIRI ± bevacizumab 🎯 Response 64.4% vs 39.2% 📈 Median PFS 15.2 vs 8.3 months HR 0.44 📊 Overall survival HR 0.56 🔥 18-month OS 72.0% vs 54.5% This is the kind of result that matters because it is not just one endpoint moving. Response matters in symptomatic disease. PFS matters in aggressive biology. OS matters always. And here, all three are positive. The practical piece is also important: FOLFIRI gives clinicians flexibility. For patients with neuropathy, prior oxaliplatin exposure, or concern about cumulative oxaliplatin toxicity, this helps support a fluoropyrimidine/irinotecan backbone with EGFR/BRAF targeting. My take: for BRAF V600E-mutant mCRC, the treatment frame has changed. This is no longer a disease where we wait for later-line targeted therapy. The targeted backbone belongs up front. @TheGutonclab @UGrewalMD @TimothyJBrownMD @OncoAlert @Onco_Nexus @ASCO @NazliDizman @LauraAlderMD @DVAraujoMD @DrBarbiOnc @LauraEsfeller @FunchainMD @YGaritaonaindia @DrSAHaddad @jgong15 @iandresmeraz @SakditadMD @RamilaShilpakar @RohitBanwar @lungoncdoc

keyboard_arrow_left Previous keyboard_arrow_right Next

This NEW OUTDOOR ICU rooftop garden may change how hospitals think about critical care recovery forever. Would you want an outdoor ICU space at your hospital? Gives critically ill patients something many haven’t experienced in months: fresh air, sunlight, and a connection to the outdoors. “I forgot what it feels like to be outside.” After 2 months in the ICU, a 29-year-old patient was taken onto the UK’s new rooftop intensive care garden—and became emotional experiencing fresh air and sunlight again. This may be the future of critical care. Could nature help reduce delirium, anxiety, stress, and even accelerate recovery? As ICU clinicians, we spend enormous effort optimizing medications, ventilation, nutrition, mobility, and technology. Perhaps we should also be optimizing access to sunlight, fresh air, and the healing power of nature. Would you want access to an outdoor healing space if you were recovering in the ICU? #CriticalCare #ICU #ICURehab #Medicine #Healthcare #ICURecovery #Delirium #Rehabilitation

Oh my goodness…#asco26 had amazing and brilliant @paltown1 research advocates! loved seeing you 💙 @FightCRC @manjuggm

@AnjeeDavis @paltown1 @FightCRC @manjuggm Ohhh, so nice to see you, Anjee!! Some of my loved ones there!! 😍

@fireflyann @ASCO @ConquerCancerFd @KRASKickers Way to go, Ann!

For breaking news and expert analysis during #ASCO26, turn to #ASCODailyNews! During and after the Meeting, ASCO Daily News has coverage of all the practice-changing research being presented. Bookmark us now: bit.ly/3NebrBH

Finnish scientists trucked in real forest dirt and grass and laid it over the gravel at four daycare yards. They let the kids dig around in it for a month. The blood tests came back with changes the researchers hadn’t expected to see so fast or so clear. The study ran at ten daycares in two Finnish cities with 75 kids aged three to five. Four of the yards got the forest treatment: about a tennis court worth of soil and grass laid over the gravel, plus planters and peat blocks the kids could dig and climb on. Three others stuck with their normal gravel yards. The last three were daycares where the kids were already visiting real forests every day. After one month, the variety of bacteria living on the kids’ skin shot up, and the kind that helps train the skin’s immune defenses jumped the most. Their gut bacteria started to look like the gut bacteria of the forest-visiting kids. Their blood showed more of the immune cells whose job is to keep the body from freaking out at harmless stuff like pollen and peanuts, and overall inflammation dropped. The kids on the plain gravel yards showed none of this. Childhood asthma in the US doubled between 1980 and 1995. Food allergies in kids jumped 50 percent between 1997 and 2011, then jumped another 50 percent between 2007 and 2021. And peanut allergies in one-year-olds tripled between 2001 and 2017. The Finnish researchers think one of the reasons is simple: kids today don’t get dirty enough. 37 percent of American preschoolers now spend an hour or less outside on a normal weekday. Their immune systems are getting trained in environments stripped of the bacteria humans have always lived around. Aki Sinkkonen, who led the study, put it in plain words: “It would be best if children could play in puddles and everyone could dig organic soil.” The Finnish government is now helping pay for daycares across the country to make the same changes.

ChiefHerbalist @HerbalistChief

2 months ago

We need to apologize to our ancestors.

393 9K 41K 4.3M 3K

The growing inaccessibility of science that you can understand by paying €27.99

What is CRI's Clinical Trial Finder, and how does it work? Understand why clinical trials matter, and discover how you or your loved ones can utilize this free tool to create a path toward possibility: bit.ly/4tXh0Z5 #ClinicalTrial #Immunotherapy

From professional development sessions to methods workshops and more, #AACR26 has something for everyone. Program Committee Chairs Paul S. Mischel and Alice T. Shaw share Friday's highlights in AACR Annual Meeting News: brnw.ch/21x1H2k

Phase II Study of Anti-PD-1/​VEGF Bispecific Antibody Ivonescimab in Patients W/ Previously Treated Metastatic Colorectal Cancer @MDAndersonNews PI: Saurav Haldar, MD NCT06959550, 90 pts trial recruiting date advanced from October 2025 to open up "early" in July 25 @SassyCell

Introducing @ASCO Early-Onset/AYA Cancers Community of Practice, official twitter handle and logo. Please consider joining our CoP to advance care-delivery, research & education for pts with cancer in the EO/AYA groups. Looking forward to connecting with the community here on X!

@AnwaarSaeed3 presented DSP107 is a 1st in class T-cell engager with very promising activity in combo w/#immunotherapy including liver mets. #colorectalcancer #cancerresearch #cancer

keyboard_arrow_left Previous keyboard_arrow_right Next

🧬 Get ready for the latest in #colorectalcancer research! On June 10 at 11 AM EST, join us for Research Updates from ASCO 2025. Dr. Smitha Krishnamurthi and Annie Delores will break down the most exciting breakthroughs in CRC care. #ASCO25 Register to... fightcrc.zoom.us/webinar/regist…

Science tikkun: a bioscience pandemic framework in a Hebrew tradition of global repair | Molecular Medicine link.springer.com/article/10.118…

It’s podcast launch day! The ImmunoVerse™️ is now streaming on all your favorite platforms! 🚀 I’m honored to kick off this new @MoffittNews podcast with the inaugural episode ft. Dr. Steven Rosenberg, my colleague, friend, mentor and Chief of the Surgery Branch @theNCI. In episode 1, we explore Dr. Rosenberg’s pioneering work in immunotherapy, how far it has come, and where it’s headed! #TheImmunoVerse 🎙️ Listen now: Moffitt.org/ImmunoVerse